Cargando…
Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer
PURPOSE: We aimed to reveal the prognostic influence of B-cell CLL/lymphoma 2 (BCL2) on molecular subtypes of breast cancer. METHODS: We analyzed 9,468 patients with primary breast cancer. We classified molecular subtypes according to the National Comprehensive Cancer Network (NCCN) and St. Gallen g...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Breast Cancer Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378580/ https://www.ncbi.nlm.nih.gov/pubmed/28382095 http://dx.doi.org/10.4048/jbc.2017.20.1.54 |
_version_ | 1782519457691729920 |
---|---|
author | Hwang, Ki-Tae Han, Wonshik Kim, Jongjin Moon, Hyeong-Gon Oh, Sohee Song, Yun Seon Kim, Young A Chang, Mee Soo Noh, Dong-Young |
author_facet | Hwang, Ki-Tae Han, Wonshik Kim, Jongjin Moon, Hyeong-Gon Oh, Sohee Song, Yun Seon Kim, Young A Chang, Mee Soo Noh, Dong-Young |
author_sort | Hwang, Ki-Tae |
collection | PubMed |
description | PURPOSE: We aimed to reveal the prognostic influence of B-cell CLL/lymphoma 2 (BCL2) on molecular subtypes of breast cancer. METHODS: We analyzed 9,468 patients with primary breast cancer. We classified molecular subtypes according to the National Comprehensive Cancer Network (NCCN) and St. Gallen guidelines, mainly on the basis of the expression of hormonal receptor (HR), human epidermal growth factor receptor 2 (HER2), and Ki-67. RESULTS: Regarding NCCN classification, BCL2 was a strong favorable prognostic factor in the HR(+)/HER2(–) subtype (p<0.001) and a marginally significant favorable prognosticator in the HR(+)/HER2(+) subtype (p=0.046). BCL2 had no prognostic impact on HR(–)/HER2(+) and HR(–)/HER2(–) subtypes. In relation to St. Gallen classification, BCL2 was a strong favorable prognosticator in luminal A and luminal B/HER2(–) subtypes (both p<0.001). BCL2 was a marginally significant prognosticator in the luminal B/HER2(+) subtype (p=0.046), and it was not a significant prognosticator in HER2 or triple negative (TN) subtypes. The prognostic effect of BCL2 was proportional to the stage of breast cancer in HR(+)/HER2(–), HR(+)/HER2(+), and HR(–)/HER2(–) subtypes, but not in HR(–)/HER2(+) subtype. BCL2 was not a prognostic factor in TN breast cancer regardless of epidermal growth factor receptor expression. CONCLUSION: The prognostic influence of BCL2 was different across molecular subtypes of breast cancer, and it was largely dependent on HR, HER2, Ki-67, and the stage of cancer. BCL2 had a strong favorable prognostic impact only in HR(+)/HER2(–) or luminal A and luminal B/HER2(–) subtypes, particularly in advanced stages. Further investigations are needed to verify the prognostic influence of BCL2 on molecular subtypes of breast cancer and to develop clinical applications for prognostication using BCL2. |
format | Online Article Text |
id | pubmed-5378580 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Korean Breast Cancer Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-53785802017-04-05 Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer Hwang, Ki-Tae Han, Wonshik Kim, Jongjin Moon, Hyeong-Gon Oh, Sohee Song, Yun Seon Kim, Young A Chang, Mee Soo Noh, Dong-Young J Breast Cancer Original Article PURPOSE: We aimed to reveal the prognostic influence of B-cell CLL/lymphoma 2 (BCL2) on molecular subtypes of breast cancer. METHODS: We analyzed 9,468 patients with primary breast cancer. We classified molecular subtypes according to the National Comprehensive Cancer Network (NCCN) and St. Gallen guidelines, mainly on the basis of the expression of hormonal receptor (HR), human epidermal growth factor receptor 2 (HER2), and Ki-67. RESULTS: Regarding NCCN classification, BCL2 was a strong favorable prognostic factor in the HR(+)/HER2(–) subtype (p<0.001) and a marginally significant favorable prognosticator in the HR(+)/HER2(+) subtype (p=0.046). BCL2 had no prognostic impact on HR(–)/HER2(+) and HR(–)/HER2(–) subtypes. In relation to St. Gallen classification, BCL2 was a strong favorable prognosticator in luminal A and luminal B/HER2(–) subtypes (both p<0.001). BCL2 was a marginally significant prognosticator in the luminal B/HER2(+) subtype (p=0.046), and it was not a significant prognosticator in HER2 or triple negative (TN) subtypes. The prognostic effect of BCL2 was proportional to the stage of breast cancer in HR(+)/HER2(–), HR(+)/HER2(+), and HR(–)/HER2(–) subtypes, but not in HR(–)/HER2(+) subtype. BCL2 was not a prognostic factor in TN breast cancer regardless of epidermal growth factor receptor expression. CONCLUSION: The prognostic influence of BCL2 was different across molecular subtypes of breast cancer, and it was largely dependent on HR, HER2, Ki-67, and the stage of cancer. BCL2 had a strong favorable prognostic impact only in HR(+)/HER2(–) or luminal A and luminal B/HER2(–) subtypes, particularly in advanced stages. Further investigations are needed to verify the prognostic influence of BCL2 on molecular subtypes of breast cancer and to develop clinical applications for prognostication using BCL2. Korean Breast Cancer Society 2017-03 2017-03-24 /pmc/articles/PMC5378580/ /pubmed/28382095 http://dx.doi.org/10.4048/jbc.2017.20.1.54 Text en © 2017 Korean Breast Cancer Society http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Hwang, Ki-Tae Han, Wonshik Kim, Jongjin Moon, Hyeong-Gon Oh, Sohee Song, Yun Seon Kim, Young A Chang, Mee Soo Noh, Dong-Young Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer |
title | Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer |
title_full | Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer |
title_fullStr | Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer |
title_full_unstemmed | Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer |
title_short | Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer |
title_sort | prognostic influence of bcl2 on molecular subtypes of breast cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378580/ https://www.ncbi.nlm.nih.gov/pubmed/28382095 http://dx.doi.org/10.4048/jbc.2017.20.1.54 |
work_keys_str_mv | AT hwangkitae prognosticinfluenceofbcl2onmolecularsubtypesofbreastcancer AT hanwonshik prognosticinfluenceofbcl2onmolecularsubtypesofbreastcancer AT kimjongjin prognosticinfluenceofbcl2onmolecularsubtypesofbreastcancer AT moonhyeonggon prognosticinfluenceofbcl2onmolecularsubtypesofbreastcancer AT ohsohee prognosticinfluenceofbcl2onmolecularsubtypesofbreastcancer AT songyunseon prognosticinfluenceofbcl2onmolecularsubtypesofbreastcancer AT kimyounga prognosticinfluenceofbcl2onmolecularsubtypesofbreastcancer AT changmeesoo prognosticinfluenceofbcl2onmolecularsubtypesofbreastcancer AT nohdongyoung prognosticinfluenceofbcl2onmolecularsubtypesofbreastcancer |